• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

GenesisCare physicians discuss PSMA-PET imaging agent Pylarify


GenesisCare doctors Kishore K. Dass, MD, Anurag Agarwal, MD, and Jerry Singer, MD, share their expert insight on the novel PSMA-PET imaging diagnostic Pylarify (piflufolastat F 18), which is FDA approved for use in patients with prostate cancer. The first US patient to receive Pylarify was treated at the GenesisCare facility in Boca Raton, Florida, where these doctors work.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.